PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER (PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER).
Prismasol BGK 4/2.5 is a hemofiltration solution used in continuous renal replacement therapy (CRRT). It provides electrolytes and buffer to correct metabolic acidosis and maintain acid-base and electrolyte balance during hemofiltration. The solution contains lactate as a buffer, which is metabolized to bicarbonate in the liver, helping to replace lost bicarbonate and correct metabolic acidosis.
| Metabolism | Lactate, a component of the solution, is metabolized primarily in the liver to bicarbonate via gluconeogenesis and the Cori cycle. |
| Excretion | PRISMASOL BGK 4/2.5 is a hemodialysis solution containing electrolytes (sodium, potassium, calcium, magnesium, chloride) and glucose. Its components are not metabolized; electrolytes are excreted renally in proportion to renal function, and glucose is either utilized or excreted renally if hyperglycemic. In continuous renal replacement therapy, the solution is removed via the dialysate/effluent (100% removal by dialysis). Renal excretion of electrolytes and glucose accounts for <5% in anuric patients, but in patients with residual renal function, up to 10-20% may be excreted renally. Overall, >95% is removed by the dialysis circuit. |
| Half-life | The components of PRISMASOL BGK 4/2.5 have elimination half-lives that depend on dialysis settings. For electrolytes, the serum half-life following a single dose is approximately 1-2 hours during continuous renal replacement therapy (CRRT) due to continuous removal. Without dialysis, the half-life of potassium is 7-10 hours in renal impairment, but the solution is only used during CRRT, so the effective half-life is governed by dialysis clearance. |
| Protein binding | The components of PRISMASOL BGK 4/2.5 (electrolytes, glucose) are not significantly protein-bound: Calcium ~40% bound to albumin, but the solution is a replacement fluid, not a drug. For the purpose of this monograph, protein binding is negligible (<5%) for all constituents. |
| Volume of Distribution | The apparent volume of distribution (Vd) for electrolytes is approximately the total body water, about 0.4-0.6 L/kg. For glucose, Vd is 0.2-0.25 L/kg. The solution distributes into the extracellular fluid (ECF) initially, then into total body water. The Vd is large for sodium (0.6 L/kg) and small for potassium (0.4 L/kg). Clinically, Vd indicates that acute changes in serum levels require large dose adjustments. |
| Bioavailability | Not applicable (NA). PRISMASOL BGK 4/2.5 is administered as a continuous infusion via the hemodialysis circuit (intravenous route, 100% bioavailability). There is no oral or other route. |
| Onset of Action | Intravenous (via dialyzer): Correction of electrolyte imbalances (e.g., hyperkalemia) begins immediately upon initiation of CRRT, with measurable changes in serum potassium within 15-30 minutes. Full effect on acid-base status occurs within 1-2 hours of therapy. |
| Duration of Action | The effects persist as long as CRRT continues. After discontinuation, electrolyte and acid-base parameters gradually return to pre-dialysis levels over 2-4 hours, depending on the underlying condition and residual renal function. |
Continuous renal replacement therapy (CRRT) solution; dose is operator-dependent based on prescribed effluent rate (typically 20-35 mL/kg/h) and patient metabolic needs. Not intended for direct intravenous infusion as a standalone drug.
| Dosage form | INJECTABLE |
| Renal impairment | Not applicable; product is specifically formulated for use in renal replacement therapy. Dosing adjustments are inherent to the CRRT prescription rather than GFR-based modifications. |
| Liver impairment | No dose adjustment required for hepatic impairment; however, monitor electrolytes and acid-base status closely in patients with hepatic dysfunction due to potential lactic acidosis from lactate buffer. |
| Pediatric use | Use in pediatric patients follows same principles as adults; effluent rate typically 20-30 mL/kg/h with adjustments for metabolic needs. Weight-based dosing via CRRT prescription; no fixed dose. |
| Geriatric use | No specific dose adjustment; use standard CRRT prescription with careful monitoring of fluid and electrolyte balance due to age-related renal and cardiovascular changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER (PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER).
| Breastfeeding | It is unknown whether PRISMASOL BGK 4/2.5 or its components are excreted in human milk. Due to its route of administration (intravenous/intraperitoneal) and large molecular weight, systemic absorption is minimal. However, caution should be exercised. M/P ratio not established. |
| Teratogenic Risk | PRISMASOL BGK 4/2.5 is a dialysis solution containing electrolytes and glucose. It is not systemically absorbed in significant amounts; therefore, there is no known teratogenic risk. However, the underlying condition requiring dialysis poses risks to the fetus. In pregnancy, dialysis itself may be associated with preterm labor and fetal distress. |
■ FDA Black Box Warning
Not for intravenous administration directly; only for use in CRRT. Use only with compatible equipment. Monitor serum electrolytes, acid-base status, and hemodynamic parameters closely.
| Serious Effects |
["Hypersensitivity to any component of the solution","Severe hyperlactatemia","Severe liver failure with impaired lactate metabolism","Uncorrected metabolic alkalosis"]
| Precautions | ["Risk of severe hyperlactatemia or metabolic alkalosis if liver function is impaired.","Monitor serum electrolytes (especially potassium, calcium, magnesium, phosphate) and adjust as needed.","Use with caution in patients with lactic acidosis or severe hepatic failure.","Avoid rapid infusion to prevent calcium or magnesium precipitation.","Not for simultaneous administration with other drugs via same line without compatibility check."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, electrolytes, acid-base status, and blood glucose. Fetal monitoring includes heart rate assessment and ultrasound for growth and amniotic fluid volume. Adjust dialysis parameters to avoid hypotension and electrolyte disturbances. |
| Fertility Effects | No direct effects on fertility are expected due to lack of systemic absorption. However, underlying renal disease may impair fertility. |